Foghorn Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Cash & Equivalents	82.04	53.92	102.87	94.53	17.26	40.59
Short-Term Investments	153.72	293.58	53.15	92.98	0	0
Cash & Cash Equivalents	235.77	347.51	156.02	187.5	17.26	40.59
Cash Growth	-32.16%	122.73%	-16.79%	986.66%	-57.48%	-
Receivables	0	0	300	0	0	0
Other Current Assets	4.42	3.89	3.54	3.18	-0.37	-0.18
Total Current Assets	240.18	351.4	459.56	190.69	16.89	40.4
Property, Plant & Equipment	42.91	49.4	56.08	62.33	3.71	2.09
Other Long-Term Assets	2.82	4.09	4.13	2.58	1.74	0.57
Total Long-Term Assets	45.74	53.48	60.21	64.91	5.46	2.66
Total Assets	285.92	404.88	519.77	255.59	22.34	43.06
Accounts Payable	6.26	5.41	3.82	3.68	3.44	2.01
Deferred Revenue	302.67	336.82	351.05	14.57	0	0
Current Debt	8.52	5.97	6.99	3.98	5.51	0
Other Current Liabilities	-259.01	-293	-313.17	-3.39	3.7	1.45
Total Current Liabilities	58.44	55.21	48.69	18.85	12.65	3.46
Long-Term Debt	36.56	45.54	51.34	78.02	11.12	7.03
Other Long-Term Liabilities	268.12	304.03	322.87	12.55	0.05	0.59
Total Long-Term Liabilities	304.67	349.57	374.21	90.56	11.16	7.62
Total Liabilities	363.11	404.77	422.9	109.41	23.81	11.08
Total Debt	45.07	51.51	58.33	82	16.63	7.03
Debt Growth	-12.49%	-11.70%	-28.86%	393.09%	136.58%	-
Retained Earnings	-471.56	-373.14	-264.26	-162.94	-94.14	-43.01
Comprehensive Income	-0.83	-3.99	-0.01	-0.01	0	0
Shareholders' Equity	-77.19	0.11	96.87	146.19	-88.02	-39.27
Net Cash / Debt	190.69	296	97.69	105.51	0.63	33.56
Net Cash / Debt Growth	-35.58%	203.00%	-7.41%	16754.15%	-98.13%	-
Net Cash Per Share	4.54	7.12	2.63	9.55	0.15	11.39
Working Capital	181.75	296.19	410.87	171.84	4.23	36.94
Book Value Per Share	-1.84	0.00	2.61	13.23	-21.00	-13.33

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).